Cellceutix Abstract for Annual Society of Clinical Oncology Meeting

BEVERLY, MA – February 4, 2013– Cellceutix Corporation (OTCBB: CTIX) (the “Company”), a clinical stage biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases, today announces that the Company is submitting an abstract for the upcoming 2013 American Society of Clinical Oncology (“ASCO”) Annual Meeting to be held in Chicago, Illinois on May 31 to June 4.  The presentation is entitled: “A Phase 1 Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic Study of Thioureidobutyronitrile (Kevetrin™), a Novel p53 Targeted Therapy in Patients with Advanced Solid Tumors.”

Key personnel, including investigators and physicians from the hospitals involved in the clinical trials of Kevetrin™, Cellceutix’s flagship anti-cancer compound being hosted at Harvard’s Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center, assisted in preparing the abstract.

The ASCO meeting gives Cellceutix an opportunity to provide a comprehensive update on the latest data from the Kevetrin clinical trials to shareholders and leaders in the scientific community as well as time for interaction with others about possible future collaborations and studies. Furthermore, it showcases Cellceutix’s novel drug and accomplishments to many of the organizations that were first introduced to Kevetrin three years ago when it was recognized at the American Association for Cancer Research as a drug on the ‘frontier’ of cancer research.

Dr. Krishna Menon, Chief Scientific Officer at Cellceutix, commented, “We are still at the early stages of the clinical trial. To date, we have not observed any dose limiting toxicities. Initial pharmacokinetic (PK) data from the clinical trial has been received and is consistent with the animal data, which is a very optimistic sign moving forward. Additional information on these PK studies will be forthcoming at ASCO. We are now looking forward to receiving data from the p21 biomarker studies which is expected in March 2013.”

Further information on the clinical trial, titled “A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin (Thioureidobutyronitrile) Administered Intravenously, in Patients With Advanced Solid Tumors,” is available at: http://clinicaltrials.gov/ct2/show/NCT01664000?term=cellceutix&rank=1